SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
PROK

Prokidney Corp. (NASDAQ:PROK)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.04-$0.02 (-1.89%)
 
Market cap
$350M
Insider Score
Health Score
Analyst consensus
Listed since
Jun 30, 2021
Market Cap$349.70M-51.4%
Revenue (ttm)$775.00K+4.2%
Net Income-$103.28M-45.4%
EPS-$0.60-9.1%
Shares Out148.17M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,901,121
Open$1.03
Previous Close$1.06
Day's Range$1.02 - $1.08
52-Week Range$0.87 - $2.65
Beta1.90
AnalystsBuy
Price Target$4.67(+349.04%)
Earnings DateMar 17, 2027

About PROK

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.

Address
2000 Frontis Plaza Blvd., Winston-Salem, NC, 27103, US
Market Cap
350 million
Employees
231
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$2.95M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 Sell

1 firm rating PROK in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From PROK’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-1.89%
5 Days
+1.96%
1 Month
-27.27%
6 Months
-40.57%
1 Year
-51.40%

$PROK stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in PROK holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by PROK's directors and management

Net Shares Purchased by Insiders−800k−400k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

PROK Estimated quarterly lobbying spending

Source: U.S. Senate LDA

PROK Revenue by Segment

$16.59MTotal
Equity-based compensation$16.42M98.95%
Rental income$174.00K1.05%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New PROK patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to PROK from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in PROK

IWMiShares Russell 2000 ETF$2.84M
VXFVanguard Extended Market ETF$2.24M
SCHASchwab U.S. Small-Cap ETF$869.52K
VTWOVanguard Russell 2000 ETF$833.13K
IWOiShares Russell 2000 Growth ETF$732.59K
SURISimplify Propel Opportunities ETF$503.09K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from PROK’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
35

News check: Q3 earnings miss on revenue coupled with reported loss outweighs leadership appointment; concrete negative business results dominate coverage.

Recent Insider Activity

Buys
0
Sells
10
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

SURISimplify Propel Opportunities ETF0.71%
BBCVirtus Biotech Clinical Trials ETF0.51%

Weight is the stock’s share of each fund’s holdings.